Post-Nasdaq Jump, Neostem Adding $35M In Public Offering
Two months after shares of Neostem Inc. made the leap to Nasdaq, the New York-based firm added some much-needed capital, raising $35 million to support its expanding cell therapy business, including a lead therapeutic candidate aimed at heart attack patients.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST